MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
ENDRA Life Sciences Cost of Revenue 2011-2026 | NDRA
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 173 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 173 K | 173 K | 173 K |
Quarterly Cost of Revenue ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 118 K | 51.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 118 K | 51.4 K | 84.8 K |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 20.81 | - | $ 1.11 B |  USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Agilent Technologies
A
|
2.91 B | $ 115.55 | - | $ 35.1 B | USA |
 |
Co-Diagnostics
CODX
|
222 K | $ 1.55 | - | $ 2.06 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 24.49 | - | $ 680 M | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
176 M | $ 15.19 | - | $ 459 M | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 118.33 | - | $ 9.76 B |  Irlanda |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Lantheus Holdings
LNTH
|
600 M | $ 84.62 | - | $ 5.71 B | USA |
 |
NeoGenomics
NEO
|
413 M | $ 9.26 | - | $ 1.19 B | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.99 B | $ 26.34 | - | $ 20 B |  Niderland |
 |
Illumina
ILMN
|
1.51 B | $ 126.74 | - | $ 20.2 B | USA |
 |
Personalis
PSNL
|
57.8 M | $ 5.52 | - | $ 327 M | USA |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 6.61 | - | $ 276 M | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Soleno Therapeutics
SLNO
|
2.7 M | $ 52.82 | - | $ 2.68 B | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
349 M | $ 87.08 | - | $ 10.9 B | USA |
 |
Twist Bioscience Corporation
TWST
|
186 M | $ 58.45 | - | $ 3.5 B | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
Myriad Genetics
MYGN
|
248 M | $ 4.75 | - | $ 440 M | USA |
 |
Waters Corporation
WAT
|
363 M | $ 309.23 | - | $ 18.4 B | USA |
 |
Interpace Biosciences
IDXG
|
14.6 M | $ 1.98 | -0.5 % | $ 8.76 M | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
4.81 M | $ 2.18 | - | $ 5.01 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 256.8 | - | $ 21.4 B | USA |
 |
Natera
NTRA
|
158 M | $ 206.16 | - | $ 20.3 B | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 9.4 | - | $ 2.04 B | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 194.2 | - | $ 21.6 B | USA |
 |
OpGen
OPGN
|
3.32 M | - | -16.95 % | $ 1.54 M | USA |